CelLBxHealth plc (ANPCY) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cotizando a $, CelLBxHealth plc (ANPCY) es una empresa del sector Healthcare valorada en 0. La acción obtiene una puntuación de 55/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 17 mar 2026CelLBxHealth plc (ANPCY) Resumen de Asistencia Médica y Tuberías
CelLBxHealth plc, formerly ANGLE plc, specializes in cancer diagnostics, offering the Parsortix system for capturing circulating tumor cells. With a focus on liquid biopsy analysis, the company serves the UK, Europe, and North America, positioning itself in the evolving landscape of personalized cancer diagnostics and research.
Tesis de Inversión
CelLBxHealth plc presents a focused investment opportunity within the cancer diagnostics sector. The company's Parsortix system addresses the growing demand for non-invasive liquid biopsy solutions, particularly in metastatic breast cancer. Key value drivers include the expansion of Parsortix system adoption in clinical research and diagnostic settings, coupled with the growth of the company's laboratory service offerings. The market capitalization stands at $0.02 billion, indicating potential for growth if the company can successfully commercialize its products and services. Upcoming catalysts include expansion of strategic partnerships and regulatory approvals for new diagnostic applications. Potential risks include competition from established diagnostic companies and the need for further clinical validation of the Parsortix system.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- CelLBxHealth plc specializes in cancer diagnostics, focusing on circulating tumor cell (CTC) capture and analysis.
- The Parsortix system is a key product, enabling non-invasive liquid biopsies for cancer research and diagnostics.
- Strategic partnerships with BioView Ltd and NuProbe USA, Inc. enhance diagnostic capabilities through assay development and NGS panel integration.
- The company offers a range of laboratory services, including CTC enrichment and custom assays, providing recurring revenue streams.
- CelLBxHealth plc rebranded from ANGLE plc in October 2025, signaling a strategic shift towards cell-based diagnostics.
Competidores y Pares
Fortalezas
- Proprietary Parsortix technology for CTC capture.
- Expertise in liquid biopsy analysis.
- Strategic partnerships with BioView and NuProbe.
- Established presence in the UK and Europe.
Debilidades
- Limited commercial presence in North America and Asia.
- Reliance on a single core technology (Parsortix).
- Relatively small market capitalization.
- Dependence on strategic partnerships for assay development.
Catalizadores
- Ongoing: Expansion of the Parsortix system into new therapeutic areas beyond metastatic breast cancer.
- Upcoming: Potential regulatory approvals for new diagnostic applications of the Parsortix system.
- Ongoing: Continued growth in laboratory service offerings, including CTC enrichment and liquid biopsy analysis.
- Upcoming: Expansion of strategic partnerships with pharmaceutical and diagnostic companies.
- Ongoing: Integration of AI and machine learning technologies into the CTC analysis platform.
Riesgos
- Potential: Competition from established diagnostic companies with greater resources and market share.
- Potential: Regulatory hurdles and delays in obtaining approvals for new diagnostic products.
- Potential: Need for further clinical validation of the Parsortix system to demonstrate its efficacy and clinical utility.
- Ongoing: Dependence on strategic partnerships for assay development and commercialization.
- Potential: Risks associated with operating in the OTC market, including limited liquidity and disclosure.
Oportunidades de crecimiento
- Expansion into New Therapeutic Areas: CelLBxHealth plc can expand its Parsortix system and related assays into new therapeutic areas beyond metastatic breast cancer, such as lung cancer, colorectal cancer, and prostate cancer. Each of these areas represents a multi-billion dollar market with significant unmet needs for improved diagnostics and monitoring tools. By developing and validating assays specific to these cancers, CelLBxHealth plc can diversify its revenue streams and capture a larger share of the liquid biopsy market. The timeline for this expansion is estimated at 2-3 years, requiring further research and development efforts.
- Geographic Expansion: CelLBxHealth plc can expand its commercial presence into new geographic markets, such as Asia-Pacific and Latin America, where the demand for advanced cancer diagnostics is growing rapidly. These regions offer significant growth opportunities due to increasing healthcare spending, rising cancer incidence rates, and a growing awareness of the benefits of liquid biopsy. Establishing partnerships with local distributors and key opinion leaders will be crucial for successful market entry. The timeline for this expansion is estimated at 3-5 years, requiring significant investment in sales and marketing infrastructure.
- Development of Companion Diagnostics: CelLBxHealth plc can leverage its Parsortix system and CTC analysis capabilities to develop companion diagnostics for targeted cancer therapies. Companion diagnostics are essential for identifying patients who are most likely to benefit from specific treatments, improving treatment outcomes and reducing healthcare costs. By partnering with pharmaceutical companies to develop and commercialize companion diagnostics, CelLBxHealth plc can generate significant revenue streams and establish itself as a key player in the personalized medicine space. The timeline for this development is estimated at 2-4 years, requiring close collaboration with pharmaceutical partners.
- Integration with Artificial Intelligence: CelLBxHealth plc can integrate artificial intelligence (AI) and machine learning (ML) technologies into its CTC analysis platform to improve the accuracy and efficiency of cancer diagnosis and monitoring. AI-powered algorithms can be used to identify subtle patterns and biomarkers in CTCs that may be missed by human observers, leading to earlier and more accurate diagnoses. This integration can also automate many of the manual steps involved in CTC analysis, reducing costs and improving turnaround times. The timeline for this integration is estimated at 1-2 years, requiring investment in AI/ML expertise and infrastructure.
- Expansion of Laboratory Service Offerings: CelLBxHealth plc can expand its laboratory service offerings to include a wider range of liquid biopsy assays and analyses, such as circulating tumor DNA (ctDNA) analysis, exosome analysis, and immune cell profiling. These additional services can provide clinicians with a more comprehensive understanding of the patient's cancer and guide treatment decisions. By offering a comprehensive suite of liquid biopsy services, CelLBxHealth plc can attract a larger customer base and generate higher revenue per customer. The timeline for this expansion is estimated at 1-3 years, requiring investment in new equipment and personnel.
Oportunidades
- Expansion into new therapeutic areas (e.g., lung cancer, colorectal cancer).
- Geographic expansion into Asia-Pacific and Latin America.
- Development of companion diagnostics for targeted therapies.
- Integration of AI and machine learning into CTC analysis.
Amenazas
- Competition from established diagnostic companies (e.g., Roche, Thermo Fisher).
- Regulatory hurdles for new diagnostic products.
- Need for further clinical validation of the Parsortix system.
- Potential for technological disruption in the liquid biopsy market.
Ventajas competitivas
- Proprietary Parsortix system for CTC capture.
- Expertise in liquid biopsy analysis and assay development.
- Strategic partnerships with leading companies in the diagnostic and pharmaceutical industries.
- Established customer base in research and clinical settings.
Acerca de ANPCY
CelLBxHealth plc, founded in 1994 and based in Guildford, UK, is a medical diagnostics company focused on developing and commercializing innovative cancer diagnostic products. Originally named ANGLE plc, the company rebranded to CelLBxHealth plc in October 2025, reflecting its strategic focus on cell-based diagnostics. The company's flagship product is the Parsortix system, a medical device designed to capture and harvest intact circulating tumor cells (CTCs) from patient blood samples. This system enables subsequent user-validated downstream analysis, providing valuable insights for personalized cancer treatment. The Parsortix system includes the PC1 system for metastatic breast cancer and the PR1 system for general CTC capture. CelLBxHealth also offers the Portrait+ CTC Staining kit, a laboratory kit for identifying and characterizing CTCs, and the CellKeep Slide, a CTC harvesting technology. Beyond product offerings, CelLBxHealth provides laboratory services, including CTC enrichment and liquid biopsy analysis. These services encompass a range of assays, such as Portrait Flex for immunofluorescence analysis, DNA damage response assessment, Portrait PD-L1 for evaluating CTCs, and custom CTC assays tailored to specific research needs. CelLBxHealth has established strategic partnerships to enhance its diagnostic capabilities, including a collaboration with BioView Ltd to develop a human epidermal growth factor receptor 2 assay kit for breast cancer and an agreement with NuProbe USA, Inc. to utilize pan-cancer next-generation sequencing (NGS) panels.
Qué hacen
- Develops the Parsortix system for capturing circulating tumor cells (CTCs) from blood samples.
- Offers the Parsortix PC1 system specifically for metastatic breast cancer patients.
- Provides the Portrait+ CTC Staining kit for identifying and characterizing CTCs.
- Offers the CellKeep Slide for CTC harvesting.
- Provides laboratory services, including CTC enrichment and liquid biopsy analysis.
- Develops and offers various CTC assays, including Portrait Flex, DNA damage response, and Portrait PD-L1.
- Partners with other companies to develop new diagnostic tools and technologies.
Modelo de Negocio
- Sells the Parsortix system and related consumables to research institutions and clinical laboratories.
- Provides laboratory services for CTC enrichment and liquid biopsy analysis.
- Generates revenue through strategic partnerships and collaborations with pharmaceutical and diagnostic companies.
- Offers custom CTC assays tailored to specific research needs.
Contexto de la Industria
The medical diagnostics industry is experiencing rapid growth, driven by advancements in personalized medicine and the increasing prevalence of cancer. Liquid biopsy, a non-invasive alternative to traditional tissue biopsies, is gaining traction as a valuable tool for cancer diagnosis, monitoring, and treatment selection. CelLBxHealth plc operates within this dynamic landscape, competing with established diagnostic companies and emerging players in the CTC analysis market. The company's Parsortix system offers a unique approach to CTC capture, potentially providing a competitive advantage in the liquid biopsy space. The global liquid biopsy market is projected to reach billions of dollars in the coming years, presenting significant growth opportunities for CelLBxHealth plc.
Clientes Clave
- Research institutions conducting cancer research.
- Clinical laboratories performing cancer diagnostics.
- Pharmaceutical companies developing targeted cancer therapies.
- Hospitals and cancer centers providing patient care.
Finanzas
Gráfico e información
Precio de la acción de CelLBxHealth plc (ANPCY): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para ANPCY.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para ANPCY.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para ANPCY.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de ANPCY en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Competidores y Pares
Liderazgo: Peter Collins
CEO
Peter Collins is the CEO of CelLBxHealth plc, managing a team of 119 employees. His background includes extensive experience in the medical device and diagnostics industries. He has held leadership positions in various companies, focusing on commercialization and market development. His expertise lies in driving growth and innovation within the healthcare sector, with a particular emphasis on cancer diagnostics and personalized medicine.
Historial: Since becoming CEO, Peter Collins has overseen the rebranding of ANGLE plc to CelLBxHealth plc, signaling a strategic shift towards cell-based diagnostics. He has also focused on expanding the company's strategic partnerships and commercializing the Parsortix system. Key milestones under his leadership include securing agreements with BioView Ltd and NuProbe USA, Inc. to enhance diagnostic capabilities.
Información de ADR de CelLBxHealth plc No patrocinado
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. ANPCY functions as a Level 1 ADR, meaning it trades over-the-counter (OTC) without needing to meet the strict listing requirements of major exchanges like the NYSE or NASDAQ. This allows U.S. investors to invest in CelLBxHealth plc more easily.
- Ticker del mercado local: ANPC trades on the London Stock Exchange in the United Kingdom.
- Nivel de ADR: 1
- Ratio de ADR: 1:1
- Ticker del mercado local: ANPC
Información del mercado OTC de ANPCY
The OTC Other tier represents the lowest tier of the OTC market, indicating that CelLBxHealth plc (ANPCY) may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and prospects compared to companies listed on major exchanges like the NYSE or NASDAQ. This tier is considered more speculative and carries higher risks.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure and transparency.
- Lower trading volume and liquidity.
- Wider bid-ask spreads.
- Higher price volatility.
- Potential for fraud or manipulation.
- Verify the company's registration and legal status.
- Review available financial reports and disclosures.
- Assess the company's management team and track record.
- Research the company's products, services, and market position.
- Evaluate the company's competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Established history as ANGLE plc prior to rebranding.
- Development of proprietary technology (Parsortix system).
- Strategic partnerships with BioView and NuProbe.
- Presence in the medical diagnostics industry.
- Management team with experience in the healthcare sector.
Lo Que los Inversores Preguntan Sobre CelLBxHealth plc (ANPCY)
¿Cuáles son los factores clave para evaluar ANPCY?
CelLBxHealth plc (ANPCY) actualmente tiene una puntuación IA de 55/100, indicando puntuación moderada. Fortaleza clave: Proprietary Parsortix technology for CTC capture.. Riesgo principal a monitorear: Potential: Competition from established diagnostic companies with greater resources and market share.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de ANPCY?
ANPCY actualmente puntúa 55/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de ANPCY?
Los precios de ANPCY se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre ANPCY?
La cobertura de analistas para ANPCY incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en ANPCY?
Las categorías de riesgo para ANPCY incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Competition from established diagnostic companies with greater resources and market share.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de ANPCY?
La relación P/E para ANPCY compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está ANPCY sobrevalorada o infravalorada?
Determinar si CelLBxHealth plc (ANPCY) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de ANPCY?
CelLBxHealth plc (ANPCY) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Limited analyst coverage and financial disclosure due to OTC listing.
- Information based on available company filings and press releases.